AAD 2023: Extensive updates from Galderma’s broad and innovative portfolio through posters and presentation sessions

Galderma is the only pure-play dermatology category leader, with more than 40 years of heritage in dermatology. Its continued commitment to delivering science and innovation across a highly differentiated portfolio is reflected in its extensive presence at AAD. More details on Galderma’s scientific poster presentations can be found below. Abstract # and Title First Author Presentation Date/Time (ET) Prurigo nodularis Abstract #45996 Nemolizumab monotherapy improves itch, skin lesions and sleep disturbance in patients with prurigo nodularis: Results from a phase 3 trial (OLYMPIA 2) Shawn Kwatra Late-breaker: Oral March 18, 2023 10:00-10:10 AM Theater B Abstract #40893 Risk of myocardial infarction in patients with prurigo nodularis in the UK Hannah Cornman Oral e-poster Abstract #44477 Cigarette smoking, alcohol use and obesity among patients with prurigo nodularis in the UK Viviane Liao Oral e-poster Abstract #44469 Risk of suicidal ideation and suicide attempt in patients with prurigo nodularis in US Anusha Kambala e-poster Abstract #44486 Potentially inappropriate medication use among older adults with prurigo nodularis in US Anusha Kambala e-poster Acne Abstract #41942 Improving acne care recommendations from personalizing acne: consensus of experts (PACE) Alison M Layton Mar 17, 2023 8:50-8:55 AM Level 1, Hall E, Center 1 Abstract #40148 Phase 3 pooled analysis of safety and efficacy of trifarotene 0.0005% cream with the adolescent population Adelaide Hebert e-poster Abstract #42077 Trifarotene in context: exploring the acne burden in Latin America Jerry Tan e-poster Abstract #42061 Trifarotene effects on the acne-related gene expression Brigitte Dreno e-poster Abstract #41944 Re-formulating the old tretinoin: unique microencapsulated tretinoin with microencapsulated benzoyl peroxide combination for acne vulgaris Hilary Baldwin e-poster Abstract #43621 An evaluation of the phototoxic and photoallergic potential of microencapsulated benzoyl peroxide and microencapsulated tretinoin (E-BPO/T, 3%/0.1%) applied topically to the skin of healthy subjects Jeffrey Sugarman e-poster Rosacea Abstract #41694 Evolution of benzoyl peroxide: microencapsulated 5% cream to improve tolerability in papulopustular rosacea Hilary Baldwin Mar 17, 2023 8:45-8:50 AM Level 1, Hall E, Center 1 Abstract #42280 Ivermectin therapy for rosacea: software platform to quantify changes in erythema and skin texture (IIT) Martin Schaller Mar 17, 2023 9:50-9:55 AM Level 1, Hall E, Center 1 Abstract #41921 Efficacy of subantibiotic doxycycline in rosacea: focus on patient reported outcomes Hilary Baldwin e-poster Abstract #42739 Micrencapsulated benzoyl peroxide 5% is well accepted by patients with rosacea: patient-reported outcomes and results from two phase 3 randomized vehicle-controlled trials Neal D. Bhatia e-poster Abstract #42421 Topical ivermectin in cular and cutaneous rosaea (IIT) Martin Schaller e-poster Sensitive skin (consumer) Abstract #42528 Subject Perception of An OTC Healing Ointment to Prevent / Heal Diaper Rash in Infants Matthew Meckfessel e-poster Abstract #42533 Comparison of Two OTC Itch Relief Products After Single Application Matthew Meckfessel e-poster Abstract #42510 Utilization of a Daily Oil-Free Facial Moisturizer with SPF 35 in Subjects with Skin of Color DiAnne Davis e-poster Abstract #42538 Efficacy, Tolerability, and Acceptability of a 2.6% Benzoyl Peroxide Acne Cleanser Specifically Designed for Sensitive Skin James Q Del Rosso e-poster Abstract #42656 Heatmap Evaluation of Facial Hydration Matthew Meckfessel e-poster Aesthetics Abstract #42408 Improvements in at-rest glabellar lines after treatment with abobotulinumtoxinA Sue Ellen Cox Mar 17, 2023 10:30-10:35 AM Level 1, Hall E, Center 1 Abstract #41680 How Glabellar Line Severity at Baseline Can Affect Efficacy in Neurotoxin Trials Joely Kaufman-Janette e-poster Abstract #42188 A Study Evaluating the Safety and Effectiveness of Hyaluronic Acid Filler for Correction of Infraorbital Hollow (IOH, Tear Trough Study) Brian Biesman e-poster Abstract #41448 Ten-year Global Post-market Safety Surveillance of Delayed Complications with a Flexible Cheek Filler Joel Cohen e-poster Abstract #41464 A Randomized, Controlled Study to Assess Effectiveness and Safety of Correction of Cheek Wrinkles Using a Biostimulatory Poly-L Lactic Acid Injectable Implant Sabrina Fabi e-poster For further information: Christian Marcoux, M.Sc. Chief Communications Officer [email protected] +41 76 315 26 50 Zach Randles-Friedman Head of U.S. Communications [email protected] +1 305 299 5700 Rachel Mooney Global Franchise Communications [email protected] +41 76 261 64 41

The release as fetched from its publisher. galderma.com ↗